ALUR

Allurion Technologies, Inc.

Company with tickers: ALUR, ALURW

CIK

1964979

CUSIP

02008G201

Shares Outstanding

15,006,253

Website

https://www.allurion.com

Investor Relations

https://investors.allurion.com/overview/default.aspx

Press releases and events scraped from the company's investor relations website. News and event listings link back to the original source.

Date	Headline
2026-03-02	Allurion Intends to Appeal NYSE Notice of Delisting, Execute Plan to Regain Compliance, and Expects to Continue Trading on NYSE
2026-02-24	Allurion Announces Exercise of Warrants for $3.0 Million in Gross Proceeds
2026-02-23	Allurion Receives U.S. FDA Approval
2026-02-03	Allurion Announces Partnership to Offer Combination Therapy with Mounjaro® (tirzepatide) at Discounted Prices
2026-01-12	Allurion Announces Preliminary Fourth Quarter and Full-Year 2025 Results
2025-11-25	Allurion Announces Initial Results on Combining the Allurion Program With Low-Dose Tirzepatide to Optimize Muscle Mass and GLP-1 Adherence
2025-11-20	New Peer-Reviewed Publication Demonstrates Superior Weight Loss and Improved Body Composition with the Allurion Smart Capsule Combined with Lifestyle Intervention Compared to Lifestyle Intervention Alone
2025-11-18	Allurion Announces Strategic Distribution Partnership with ProSurg Medical in Brazil to Pioneer New Approach Focused on Metabolically Healthy Weight Loss
2025-11-12	Allurion Reports Third Quarter 2025 Financial Results and Provides Business Update
2025-11-11	Allurion Passes Critical FDA Milestones, Enters Into Transaction to Exchange All Outstanding Debt That Would Result in the Company Being Debt-Free, and Announces a $5 Million Private Placement Financing